渤健公司宣布，其研发的利替利单抗（Litifilimab）已获得美国食品药品监督管理局（FDA）授予的突破性疗法认定，适应症为皮肤红斑狼疮。该疾病目前尚无针对性的靶向治疗方案，此次认定标志着针对这一未满足医疗需求的治疗研发取得重要进展。
渤健公司宣布，其研发的利替利单抗（Litifilimab）已获得美国食品药品监督管理局（FDA）授予的突破性疗法认定，适应症为皮肤红斑狼疮。该疾病目前尚无针对性的靶向治疗方案，此次认定标志着针对这一未满足医疗需求的治疗研发取得重要进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.